Impact of TP53 mutation and 17p deletion in mantle cell lymphoma

Leukemia

Volumn 25, Issue 12, 2011, Pages 1904-1908

  Halldorsdottir A M ^a   Lundin, A ^a   Murray, F ^a   Mansouri, L ^a   Knuutila, S ^b   Sundstrom C ^a   Laurell, A ^c   Ehrencrona, H ^d   Sander, B ^e   Rosenquist, R ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; GENOMIC DNA; PROTEIN P53;

CHROMOSOME 17P; CHROMOSOME DELETION; EXON; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HUMAN; LETTER; MANTLE CELL LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; COHORT STUDIES; FEMALE; GENE DELETION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 83555173456     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.162     Document Type: Letter

References (17)

1. Cheung KJ, Horsman DE, Gascoyne RD. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol 2009; 146: 257-269.
2. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007; 12: 303-312. (Pubitemid 47539312)
3. Halldorsdottir AM, Sander B, Goransson H, Isaksson A, Kimby E, Mansouri M et al. High-resolution genomic screening in mantle cell lymphoma-specific changes correlate with genomic complexity, the proliferation signature and survival. Genes Chromosomes Cancer 2010; 50: 113-121.
4. Greiner TC, Dasgupta C, Ho VV, Weisenburger DD, Smith LM, Lynch JC et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci USA 2006; 103: 2352-2357. (Pubitemid 43271673)
5. Rubio-Moscardo F, Climent J, Siebert R, Piris MA, Martin-Subero JI, Nielander I et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 2005; 105: 4445-4454. (Pubitemid 40720793)
6. Swerdlow SH, Campo E, Seto M, Müller-Hermelink HK. Mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris N, Jaffe ES, Pileri SA, Stein H, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 4th edn, vol. 2. World Health Organization: Lyon, France, 2008, pp 229-232.
7. Zainuddin N, Murray F, Kanduri M, Gunnarsson R, Smedby KE, Enblad G et al. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. Leuk Res 2011; 35: 272-274.
8. Flordal Thelander E, Ichimura K, Collins VP, Walsh SH, Barbany G, Hagberg A et al. Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. Leuk Res 2007; 31: 1219-1230.
9. Hartmann EM, Campo E, Wright G, Lenz G, Salaverria I, Jares P et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 2010; 116: 953-961.
10. Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, Anderson JR et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996; 87: 4302-4310. (Pubitemid 26152272)
11. Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996; 87: 3351-3359. (Pubitemid 26115366)
12. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2: a001008.
13. Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 2010; 24: 2072-2079.
14. Bea S, Ribas M, Hernandez JM, Bosch F, Pinyol M, Hernandez L et al. Increased number of chromosomal imbalances and highlevel DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999; 93: 4365-4374. (Pubitemid 29279280)
15. Salaverria I, Zettl A, Bea S, Moreno V, Valls J, Hartmann E et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expressionbased proliferation signature. J Clin Oncol 2007; 25: 1216-1222. (Pubitemid 46640567)
16. Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112: 3322-3329.
17. Young KH, Leroy K, Moller MB, Colleoni GW, Sanchez-Beato M, Kerbauy FR et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008; 112: 3088-3098.